Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

December 23, 2022

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2026

Conditions
Nonalcoholic Fatty LiverOsteoporosis, Postmenopausal
Interventions
DRUG

Denosumab

60 mg (1ml) administered subcutaneously once every 6 months for 12 months (totally 2 injections). Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.

DRUG

Alendronate Sodium

70 mg (1 tablet) administered per os once weekly for 12 months. Patients will also be supplemented with calcium carbonate (1000 mg/d) and cholecalciferol (800 IU/day), according to the recent guidelines.

Trial Locations (3)

54642

"Department of Endocrinology, Hippokration General Hospital of Thessaloniki", Thessaloniki

56403

1st Department of Obstetrics and Gynecology, School, of Medicine, Aristotle University of Thessaloniki, Thessaloniki

56429

424 General Military Hospital, Thessaloniki

All Listed Sponsors
collaborator

424 General Military Hospital

OTHER

lead

Aristotle University Of Thessaloniki

OTHER